Advertisement
OtherArticle

Preclinical metabolism and disposition of TP0473292, a novel oral prodrug of the potent metabotropic glutamate 2/3 receptor antagonist TP0178894 for the treatment of depression

Shoko Inatani, Motoki Ochi, Kohnosuke Kinoshita, Jun-ichi Yamaguchi and Hiromi Endo
Drug Metabolism and Disposition February 8, 2023, DMD-AR-2022-001116; DOI: https://doi.org/10.1124/dmd.122.001116
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherArticle

Preclinical DMPK of prodrug for mGlu2/3 receptor antagonist

Shoko Inatani, Motoki Ochi, Kohnosuke Kinoshita, Jun-ichi Yamaguchi and Hiromi Endo
Drug Metabolism and Disposition February 8, 2023, DMD-AR-2022-001116; DOI: https://doi.org/10.1124/dmd.122.001116
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement